Effect of a WeChat Platform-based Management Intervention on Blood Pressure Control

NCT04682015 | Unknown

• 1 other identifier: WMU1H-HTN
• Study Type: interventional
• Target: 436
• Locations: 0 countries
• Sites: N/A

Brief Summary

WeChat is the largest and most popular social media platform in China, In this study, investigators will evaluate the use of management program delivered via WeChat platform in patients with hypertension.

Conditions

Hypertension

Outcome Measures

Primary Outcomes (1)

• Proportion with controlled blood pressure at 12 months (defined by ambulatory blood pressure monitoring )

  mean 24-hour ambulatory blood pressure monitoring (ABPM) \<130/80 mmHg, day time blood pressure \<135/85 mmHg, and nocturnal blood pressure \<120/70 mmHg

  12 months

Secondary Outcomes (3)

• Systolic blood pressure (mmHg) at 12 months

  12 months

• Diastolic blood pressure (mmHg) at 12 months

  12 months

• Medication adherence at 12 months

  12 months

Study Arms (2)

Intervention

EXPERIMENTAL

The intervention group will be enrolled into WeChat platform. Participants will receive health education materials, monitor blood pressure at home and sent the blood pressure record to the platform and consult doctors online via platform.

Other: WeChat platform group

Control

NO INTERVENTION

Control group will receive usual care and follow up in hospitals and community health centers.

Interventions

WeChat platform group OTHER

Participants in the intervention group will receive educational messages related to hypertension, such as impact of hypertension on cardiovascular system, lifestyle adjustment and side effects of antihypertensive drugs. Participants will be reminded to take their blood pressure regularly and enter the blood pressure readings into the WeChat platform. If participants enter extremely high or low readings, they will be asked to seek medical help from doctors. Participants can also consult doctors online via WeChat platform by text and voice messages, or voice calls.

Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged ≥ 18 years with confirmed diagnosis of hypertension
• Office systolic blood pressure (SBP)≥140 mmHg and/or diastolic blood pressure (DBP)≥90 mmHg, or ambulatory blood pressure monitoring (ABPM) indicating 24- hour SBP ≥130 mmHg and/or DBP ≥80 mmHg and/or daytime SBP ≥135 mmHg and/or DBP ≥85 mmHg and/or nocturnal SBP ≥120 mmHg and/or DBP ≥70 mmHg.
• Patients have smart phone and often use WeChat to communicate with others (including written interaction)
• Patients are willing and able to give informed consent for participation in the trial

You may not qualify if:

• Secondary hypertension
• Hypertensive emergency: defined as severe elevations in BP (SBP ≥180 mmHg and/or DBP≥120mmHg) associated with evidence of new or worsening target organ damage, including hypertensive encephalopathy, intracranial hemorrhage, cerebral hemorrhage, subarachnoid hemorrhage, cerebral infarction, heart failure, acute coronary syndrome (unstable angina, acute myocardial infarction), aortic dissection, perioperative hypertension, preeclampsia, and eclampsia
• Refractory hypertension: defined as failure to control BP despite lifestyle changes and use of at least 5 antihypertensive agents of different classes, including a thiazide-type diuretic and a mineralocorticoid receptor antagonist
• Pregnancy or lactation or having pregnancy plan during the study period
• Life expectancy less than 1 year
• Participation in another clinical study or clinical trial in the 3 months prior to the confirmation of eligibility or current user of WeChat platform provided by hypertension center of the first affiliated hospital of Wenzhou medical university

Sponsors & Collaborators

• First Affiliated Hospital of Wenzhou Medical University: lead

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Study Officials

• GaoJun Wu

  hypertension center of the first affiliated hospital of Wenzhou medical university

  PRINCIPAL INVESTIGATOR

Central Study Contacts

GaoJun Wu

CONTACT

+86 13758715199; liujunemail1@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 20, 2020
• First Posted: December 23, 2020
• Study Start: February 18, 2021
• Primary Completion: December 31, 2022
• Study Completion: December 31, 2022
• Last Updated: February 9, 2021

Record last verified: 2020-12